# NEXT SESSION — BD Platform Quality & Trust Sprint

**Written:** 2026-05-23  
**Session focus:** Quality & Trust Sprint — dossier bugs fixed, QA audit, ground truth expansion, provenance design

---

## What Was Accomplished This Session

### ✅ Bug Fix 1: Molecule Tab Always Shown
- `_buildDrugDossierBody` was hiding the Molecule tab when `molData=null`
- Fixed: tab always rendered; shows "Not yet profiled" message when no data

### ✅ Bug Fix 2: Trials + Overlap Populating Correctly
- `openDrugEntityModal` was fetching from `drug_areas` which has no overlap columns
- Fixed: now fetches from `drug_area_scores` in parallel and merges by area_id
- Added fallback to `drugs.overlap` when area scores return null (handles tl1a/ibd area_id mismatch)

### ✅ Task 1: Entity Dossier QA Audit
- Audited 6 companies + 6 drugs across all dossier tabs
- 9 bugs found; 6 fixed immediately in the same session
- Report: `docs/entity_dossier_qa_report.md`

### ✅ Task 2: Ground Truth Expansion
- Expanded validation_tests from 28 → 61 tests
- Added 23 cross-area tests (TSLP, FcRn, IL-4Rα)
- Added 10 `not_hallucinated` tests for partner_company and drug_name fields
- All 61 tests passing

### ✅ Task 3: Source Verification Coverage Audit
- Confirmed: source_url is 0% populated across all `drug_area_scores` rows
- 42 Direct-overlap drugs have no source URL
- Priority remediation ranking: TL1A (ibd) first, then FcRn, TSLP, IL-4Rα
- Report: `docs/source_verification_audit.md`

### ✅ Task 4: Company Coverage Audit
- 60 active companies; 37 enriched; 23 unenriched
- Top 20 enrichment priority companies identified
- Healthy/Medium/Critical tier classification
- Report: `docs/company_coverage_audit.md`

### ✅ Task 5: Hallucination Defense
- Added 10 `not_hallucinated` validation tests
- Covers: partner_company self-reference, acquired-company leakage, drug name accuracy
- Fixed 3 data issues found:
  - dupilumab.partner_company='Sanofi' (self-reference) → null
  - nipocalimab.partner_company='Momenta Pharmaceuticals' (acquired 2020) → null
  - tulisokibart.partner_company='Prometheus Biosciences' (acquired 2023) → null

### ✅ Task 6: Confidence Badges in Dossier Header
- Added ✓ Confirmed / ≈ Supported / ~ Inferred / ? Unverified badges to drug dossier header chips
- All drugs currently show `?` — will resolve as enrichment runs populate source_url
- Deployed: commit `577ba0e`

### ✅ Task 7: Provenance Schema Design (design only)
- Full architecture documented: `docs/provenance_architecture.md`
- Three new tables designed: `enrichment_runs`, `provenance_events`, `assertion_history`
- Migration file ready to apply: `migrations/v16_provenance.sql`
- **NOT yet applied to Supabase** — apply when ready to implement enrichment_run_id tracking

### ✅ Task 8: Dossier Enhancement Plan (design only)
- `docs/dossier_phase2.md` — full roadmap for transforming dossier into intelligence product
- Company dossier: Cross-Area Aggregation, Signals View, Evidence View, Validation Status
- Drug dossier: Coverage Score, Strategic Value Score, Evidence Sources Panel, Change History
- Implementation priority table with effort/value estimates

### ✅ Data Quality Fixes Applied (Supabase)
- 9 `drug_area_scores` classification corrections:
  - tulisokibart, duvakitug, afimkibart, spy002, spy072 → ibd: Watch → Direct
  - tezepelumab → tslp: Watch → Direct
  - nipocalimab, efgartigimod, rozanolixizumab → fcrn: Watch → Direct
  - astegolimab, itepekimab → tslp: Watch → Direct

---

## What Was Done Since This File Was Last Written

### ✅ v16 Migration Applied (2026-05-23 Session 3)
- `enrichment_runs` table created + run_id columns added to drugs / drug_area_scores / company_profiles

### ✅ SPY072 IBD Overlap Corrected (Session 3)
- Reverted Direct → Adjacent: anti-TL1A rheumatology program (PsA/axSpA), not IBD
- Rule documented: target-lens Direct ≠ disease-area-lens Direct

### ✅ P1: Source Evidence Tracking in Enrichment Pipeline (Session 4, commit `01141bf`)
- `source_url` + `confidence_level` now written to `drug_area_scores` on every enrichment run
- `enriched_model` written to `drug_area_scores` (v16)
- `last_enriched_model` written to `drugs` and `company_profiles` (v16)
- Prompt: `confidence_level` REQUIRED; inferred must explain why in `overlap_rationale`
- Tested on caldera/cld-423; 61/61 validation tests passing

---

## Highest Priority for Next Session

### 🔴 P0: Run enrichment to populate source_url in production
v16 is applied and the write path is fixed (commit `01141bf`). Now actually run enrichment to populate `drug_area_scores.source_url` for the 42 Direct-overlap drugs that still have `source_url=null`.

Start with caldera (smallest, lowest risk), then spyre, then sanofi/abbvie/roche.

```bash
cd "$WS" && python3 scripts/company_enrichment.py --company caldera --area tl1a
```

After each run: verify `drug_area_scores.source_url` is non-null for that company's drugs.  
All 61 validation tests should continue passing after every run.

### 🟡 P2: Enrich Priority Companies (company_coverage_audit.md)
Top unenriched companies: Regeneron, Lilly, Novartis, Pfizer, Gilead, J&J, BMS, Amgen, Takeda, Boehringer Ingelheim  
Run enrichment for the Critical tier companies first.

### 🟡 P3: Dossier Phase 2 — Coverage + Strategic Value Chips (low effort, high value)
From `docs/dossier_phase2.md`:
- **Coverage Score chip** — client-side computation, no schema change needed
- **Strategic Value Score chip** — client-side computation from overlap+stage+BD profile
- Both are "Ship next session" priority in the roadmap table

### 🟡 P4: Roche Catalyst Deduplication
Roche has ~10 near-duplicate catalysts: AMETRINE appears 3×, QX031N appears 4×.  
Use the same dedup pattern from `docs/catalyst_quality_diagnosis.md`:
- Preview: `SELECT COUNT(*) WHERE company_id='roche'` grouped by label
- Delete duplicates keeping highest `id`
- Add unique constraint on `(company_id, area_id, label)`

### 🟢 P5: Duvakitug Molecule Intelligence
duvakitug has no `molecule_intelligence` record. Run targeted molecule enrichment:
- PF-06480101 / duvakitug is an anti-TL1A monoclonal antibody (humanized IgG4)
- Source: Sanofi/Pfizer co-dev; clinical data from ARTEMIS-UC, ARTEMIS-CD trials

---

## Architecture State (as of 2026-05-23)

```
DB (Supabase):
  enrichment_runs         ← live (v16 applied 2026-05-23)
  provenance_events       ← DESIGN ONLY (v17 not designed yet)  
  assertion_history       ← DESIGN ONLY (v18 not designed yet)
  drugs                   ← live; last_enriched_model written on every enrichment (v16)
  drug_area_scores        ← live; source_url=0% in prod — enrichment not yet re-run
  company_profiles        ← live; 37/60 enriched
  validation_tests        ← live; 61 tests, all passing
  catalysts               ← live; Roche dedup pending
  molecule_intelligence   ← live; duvakitug missing

UI (GitHub Pages - commit 577ba0e):
  Entity dossier          ← live; molecule tab + overlap bugs fixed
  Confidence badges       ← live; showing ? until source_url populated
  Company dossier         ← live; 5 tabs
  Drug dossier            ← live; 3 tabs (Phase 2 features in design)
```

---

## Known Issues

| Issue | Severity | Status |
|-------|----------|--------|
| drug_area_scores.source_url = 0% | High | Write path fixed (01141bf); needs enrichment re-run (P0) |
| fg-m701 area_id='atopy' (should be 'tl1a') | Medium | Not fixed — needs PATCH |
| Roche catalyst near-duplicates (~10) | Medium | Needs P4 dedup |
| duvakitug has no molecule_intelligence | Low | Needs P5 enrichment |
| Confidence badges all show '?' | Low | Will resolve once enrichment re-run populates source_url |

---

## Code Deployed This Session

**Commit `577ba0e`** on `kyleklaassen-dev/bd-dashboard` (GitHub Pages):
- Drug dossier Molecule tab always shown
- Drug dossier overlap now reads from `drug_area_scores` (not `drug_areas`)
- Overlap fallback to `drugs.overlap` when area scores return null
- Confidence badges (✓ ≈ ~ ?) in drug dossier header chips
- All 9 QA bugs patched

**Commit `01141bf`** on `scripts/company_enrichment.py`:
- `_AREA_SCORE_FIELDS` expanded: `source_url` + `confidence_level` now flow to `drug_area_scores`
- `enriched_model` written to `drug_area_scores` on every enrichment write (v16 column)
- `last_enriched_model` written to `drugs` and `company_profiles` on every write (v16 columns)
- Prompt hardened: `confidence_level` REQUIRED; `inferred` must explain why in `overlap_rationale`
- `source_url` prompt clarified: priority order CT.gov → company IR → press release; never fabricate

---

## Quick Reference

**Deploy to GitHub Pages:**
```bash
WS="/sessions/wonderful-dazzling-pasteur/mnt/BD Platform"
TMP=$(mktemp -d)
TOKEN=$(cat "$WS/.github_token")
git clone "https://$TOKEN@github.com/kyleklaassen-dev/bd-dashboard.git" "$TMP"
cp "$WS/index.html" "$TMP/index.html"
cd "$TMP" && git add index.html && git commit -m "..." && git push
```

**Supabase REST PATCH:**
```bash
SUPA_URL="https://[project-ref].supabase.co"
KEY=$(cat "$WS/.supabase_service_key")
curl -s -X PATCH "$SUPA_URL/rest/v1/[table]?[filter]" \
  -H "apikey: $KEY" -H "Authorization: Bearer $KEY" \
  -H "Content-Type: application/json" -H "Prefer: return=representation" \
  -d '{"field": "value"}'
```

**Validate ground truth:**
```bash
cd "$WS" && python3 scripts/validate_ground_truth.py
```

**Supabase dashboard:** [Dashboard → SQL Editor for v16 migration]

**Files to read before editing index.html:**
- `memory/MEMORY.md` → `user_platform_context.md` → design principles
- `docs/dossier_phase2.md` → Phase 2 roadmap
- `docs/provenance_architecture.md` → planned schema
